Generic molecule: axitinib
Approval date: Jan. 27
The scoop: This twice-a-day pill represented another approval of a targeted cancer drug for Pfizer ($PFE) for treating kidney cancer. In 2011, Pfizer nabbed an FDA OK for its non-small cell lung cancer treatment Xalkori. Pfizer also markets two other drugs for advanced kidney cancer, Sutent and Torisel. Inlyta joined a crowded market and Pfizer is only forecast to earn about $500 million from the drug.